Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. - Wikidata - awgldk - TriplyDB

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

http://www.wikidata.org/entity/Q35863422

about

Cognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014 Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease Rat butyrylcholinesterase-catalysed hydrolysis of N-alkyl homologues of benzoylcholine Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity Hippocampal memory enhancing activity of pine needle extract against scopolamine-induced amnesia in a mouse model Structural grey matter changes in the substantia innominata in Alzheimer's disease and dementia with Lewy bodies: a DARTEL-VBM study Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study.Cortical Thickness in Dementia with Lewy Bodies and Alzheimer's Disease: A Comparison of Prodromal and Dementia Stages.A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia.Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects.Evaluation and management of the non-motor features of Parkinson's disease.Divergent brain functional network alterations in dementia with Lewy bodies and Alzheimer's disease Multivariate spatial covariance analysis of 99mTc-exametazime SPECT images in dementia with Lewy bodies and Alzheimer's disease: utility in differential diagnosis Intervening in the neuropsychiatric features of Parkinson's disease.Phenserine.Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of disease.Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer's disease.Cognitive Impairment Associated with Parkinson's Disease: Role of Mitochondria.Clinical features of dementia with lewy bodies in 35 Chinese patients.Treatment of dementia with lewy bodies Rivastigmine in Parkinson's disease dementia.Treatment of dementia with Lewy bodies and Parkinson's disease dementia.Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management.Cognitive impairment and dementia in Parkinson's disease: practical issues and management.Dementia in older people: an update.A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders.Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline.Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Comprehensive treatment of dementia with Lewy bodies.Insular atrophy at the prodromal stage of dementia with Lewy bodies: a VBM DARTEL study.Comparative Studies on Behavioral, Cognitive and Biomolecular Profiling of ICR, C57BL/6 and Its Sub-Strains Suitable for Scopolamine-Induced Amnesic Models.A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies.Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients.Effects of acute tryptophan depletion on neuropsychological and motor function in Parkinson's disease.Covariance 99mTc-exametazime SPECT patterns in Alzheimer's disease and dementia with Lewy bodies: utility in differential diagnosis.Neuropsychological profile of a Filipino gentleman with X-linked dystonia-parkinsonism: a case report of Lubag disease.Yuk-Mi-Jihwang-Tang, a Traditional Korean Multiple Herbal Formulae, Improves Hippocampal Memory on Scopolamine Injection-Induced Amnesia Model of C57BL/6 Mice.Donepezil enhances Purkinje cell survival and alleviates motor dysfunction by inhibiting cholesterol synthesis in a murine model of Niemann Pick disease type C.Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.

P2860

Q28073680-7DEE886F-8EC5-463C-A1FC-62B693FAEE30 Q28085513-CE98CD00-F4CF-4BC9-9DF4-801E1719DED0 Q28583696-2A2BCAB8-D617-4758-A31F-3C1AE4CAD51B Q28586552-2626E882-6B7B-46F8-B259-2797914398B6 Q30650444-C0535883-19A7-403D-93E9-B616F8D62899 Q33697892-392DBA5F-EF1B-4EA0-A16B-019F35E6F844 Q34032505-6CE815A6-7DDD-4E73-8203-DFED84FB4765 Q35203115-25D1F6DC-F54B-41FA-B653-A9E0BD981960 Q35659990-D2031F4F-3522-4336-8E05-D771E8A053AC Q36118555-132B0986-D2CC-4889-9772-967C53345D96 Q36135045-7DC16CD0-ADE7-4A8A-9AAD-043FFF680126 Q36443721-1F6A95CC-406F-485F-A829-57994A982037 Q36444633-192211F1-30E5-4B68-8091-CBBE7A7A2C0E Q36745127-CE1740DB-9D71-421F-BB77-C239460A42F1 Q36847266-4CAE895E-A5A7-440D-BDA9-48DC23770681 Q36861622-5BFBE47D-26FC-4FF5-9E3A-8A05CBA382D7 Q37039444-49009E29-5458-431B-B489-8AD2C8237ACF Q37145718-0C53F86C-875B-4A16-9AC4-9C4B8FEEEEBB Q37168743-0E5467C2-B2BB-4A86-913B-13CF5E6D11B3 Q37497482-5BD6F6BB-3C6E-48A7-A71C-644B0745A65B Q37552865-B3CBA9A7-57A4-4F1D-822D-62986AC3FA9F Q37556550-EC7B7281-D184-4E9B-896E-E5B76B16CEF8 Q37942219-C4E854AF-51F1-4B28-9727-AA06B514ADF5 Q38107409-387AB687-B02B-470F-893A-5F52C105DB2C Q38206499-C4427CF7-A501-4123-B976-953E960869E0 Q38264846-D30EAA49-F44C-4C1C-A734-83E2D1D4DCCA Q38851564-1A6705B8-631A-465B-8CBC-1CC5A0E413BE Q38961546-B5625872-9A3D-4387-82AC-4282BE7B3DB2 Q39038234-1B67F281-4490-4EE7-A163-753307D2C11E Q41317541-3AAA8C41-DEED-4ED2-B10D-EE6849E589A2 Q41534288-EE3C2A6B-6509-4E35-8D6E-5BA4ED9F94CF Q41573979-660E2287-6193-4D1D-83FE-084F4120C2C4 Q44790322-5B73CF10-4C3B-450C-92A1-01141017BE4D Q44908766-7C3B5CC9-B28F-4A5C-91EA-F8E1062EA681 Q46001712-B4A1B317-5A2C-44D5-86D6-343D65441EEB Q48371182-F430599A-4E9C-4713-B957-F1BB0403A9AA Q49109479-BC84BCE0-A85B-4DFE-9BAE-E1BF2A5E703C Q50532485-ADD9CB07-4C1D-4B37-8386-58ABA9016CC0 Q52647428-7371A0EC-9CD4-4B9D-8993-6330C48CD77C Q53377510-A851F250-1425-4E11-8D86-BE32A2B75F77

P2860

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

http://www.wikidata.org/entity/Q35863422

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

@ast

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

@en

type

label

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

@ast

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

@en

prefLabel

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

@ast

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

@en

P1433

Q35863422-31093C4F-E4DE-4C51-8DE8-833F8D130C49

P1476

Q35863422-8602FC18-371C-4B12-BD09-7BA247C092B2

P2093

Q35863422-579777B7-68B7-4A4C-804B-1F857177957D

Q35863422-6E409730-AAE4-40D0-8A17-80D4C65DEFC7

P2860

Q35863422-0195929B-2DBD-4C3C-BA41-5C0A676351B7

Q35863422-13B2EC93-0E40-4378-B50D-95B4AC38EA2A

Q35863422-13D9465A-3CD7-4492-A51B-A7F785152C8D

Q35863422-2E4A36EA-9380-4052-BCBC-B0CACC793BF5

Q35863422-2EF4E01B-4560-441D-ABA9-2769AC3779F9

Q35863422-2F241DD8-92B3-4501-A372-4F8E02CDA794

Q35863422-489B72CC-8978-47CE-8D70-C16C1776215A

Q35863422-5903B339-B865-4736-9535-3130D3A27BA4

Q35863422-66D14F0C-3F87-4BF8-9AD5-4A77448430BA

Q35863422-6AF64A82-7EAC-4E50-943E-06665600BA58

P304

Q35863422-1D508CED-A5A4-4F3B-92BD-328AC9586E79

P31

Q35863422-201B5F8D-3B89-4BF9-BDED-6A46DC1F8280

P356

Q35863422-3912B676-C3EF-4A57-98B2-3903F729E7FB

P433

Q35863422-FE1BFA2F-C4BC-41CF-B33B-C3705255C8D9

P478

Q35863422-B9B3D9CE-0606-4479-9038-A54274DE0B61

P50

Q35863422-6C2A8B30-689B-493D-9B71-1AEC89FE7BA1

P577

Q35863422-6DB5A6C7-39AC-4B41-9710-DD166F552A41

P5875

Q35863422-207F05F3-1E63-4DFD-8CA7-4011DA7F3830

P698

Q35863422-130CF8D4-088D-4241-8DB5-7C0D1C4595CE

P921

Q35863422-14EEF845-3DCF-460C-841C-70221811F115

Q35863422-B605C7C8-89DA-4122-84BA-5AF137A0C58C

P356

0891988704267463

P1433

Journal of Geriatric Psychiatry and Neurology

P1476

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

@en

P2093

Ian G McKeith

http://www.w3.org/2001/XMLSchema#string

Urs P Mosimann

http://www.w3.org/2001/XMLSchema#string

P2860

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.

The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease.

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system.

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease.

Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism.

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.

Pathology and neurotransmitter abnormalities of dementia with Lewy bodies.

P304

164-171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0891988704267463

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8399684

http://www.w3.org/2001/XMLSchema#string

P698

15312280

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease